Drug discovery is a process of uncovering new potential candidates for disease treatment. Unfortunately, the overall success rate of drug development is only 1 - 4 % with 90% failure in clinical developmental stages. Their inadequate ADMET qualities being the root cause of the majority of failures. Additionally, the process is demanding, spanning a long 9-12 years. Today, novel drug discovery research takes approximately ~1 billion dollars which largely includes the cost of chemical synthesis of

X-HTVS, the all-new addition to the PRinS3 platform, is now available. With this molecular docking-based application, high throughput screening of gigantic libraries of potential drug candidates and a good number of targets is now possible simultaneously with only a few simple steps.

The traditional procedure of discovering new drugs is challenging and time-consuming, often having very low success rates at that. To date, scientists have to go through a very tedious process of research, selection, and synthesis of drug candidates before they can be tested in multiple levels of pre-clinical and clinical trials.

Bruton Tyrosine Kinase (BTK) plays a crucial role in various diseases like Chronic lymphocytic leukemia, Mantle cell lymphoma, Rheumatoid Arthritis, and Psoriatic Arthritis thus making it an attractive target for drug development.

In the fast-paced world of drug discovery, researchers constantly seek innovative solutions to accelerate the process while maintaining accuracy and efficiency.